While Biogen's Q4 earnings and sales exceeded expectations, the disappointing EPS guidance for 2025 could lead to negative investor sentiment and a potential short-term decline in stock price. Investors often react negatively to future guidance that falls short of expectations, as it may indicate potential challenges ahead.